Efficacy and Safety of the Biosimilar IBI301 Plus Standard CHOP (I-CHOP) in Comparison With Rituximab Plus CHOP (R-CHOP) in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): A Randomized, Double-Blind, Parallel-Group, Phase 3 TrialYuqin Song, Xin Du, Hui Zhou et al.|Advances in Therapy|2021Cited by 19
Using an in vitro xenoantibody-mediated complement-dependent cytotoxicity model to evaluate the complement inhibitory activity of the peptidic C3 inhibitor Cp40Junxiang Wang, Gang Chen, Lu Wang et al.|Clinical Immunology|2015Cited by 16
Identification and characterization of a TLR13 gene homologue from Laodelphax striatellus involved in the immune response induced by rice stripe virusXue Zhou, Fei Ma, Ping Jin et al.|Journal of Integrative Agriculture|2020Cited by 8
Antibody responses to SARS‐CoV‐2 Omicron infection in patients with hematological malignancies: A multicenter, prospective cohort studyJun Li, Yi Liu, Xia Wei et al.|Journal of Medical Virology|2023Cited by 4